20 October 2022 in Molecular Cell
SSSantiago Sandoval-Motta
+1
Germ cells are subject to exogenous retrovirus infections occasionally resulting in the genomic integration of retroviral gene sequences. These endogenized retroviruses (ERVs) are found throughout mammalian genomes. Initially thought to be inert, it is now appreciated that ERVs have often been co-opted for complex physiological processes. However, unregulated ERV transposition and expression are a threat to cellular fitness and genomic integrity, and so mammalian cells must control ERVs through pre- and post-transcriptional mechanisms. Here, we provide a field guide to the molecular machinery that identifies and silences ERVs.
26 April 2024 in EBioMedicine
28 December 2023 in bioRxiv
Single cell RNA sequencing (scRNA-seq) is revolutionizing the study of complex biological systems. However, most sequencing studies overlook the contribution of transposable element (TE) expression to the transcriptome. In both scRNA-seq and bulk tissue RNA sequencing (RNA-seq), quantification of TE expression is challenging due to repetitive sequence content and poorly characterized TE gene models. Here, we developed a tool and analysis pipeline for Single cell Transposable Element Locus Level Analysis of scRNA Sequencing (Stellarscope) that reassigns multi-mapped reads to specific genomic loci using an expectation-maximization algorithm. Using Stellarscope, we built an atlas of TE expression in human PBMCs. We found that locus-specific TEs delineate cell types and define new cell subsets not identified by standard mRNA expression profiles. Altogether, this study provides comprehensive insights into the influence of transposable elements in human biology.
30 January 2026 in Cancer Science
Tumor mutational burden (TMB) is a key biomarker for predicting the response to immune checkpoint inhibitors (ICIs). However, its predictive accuracy in real‐world clinical practice, particularly in Asian populations, remains inadequately evaluated. We addressed this issue by analyzing real‐world data from 63,952 patients registered in the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) database, which integrates genomic and clinical information from Japanese patients with various advanced solid tumors. We assessed the therapeutic efficacy of pembrolizumab in 1899 patients who underwent one of three comprehensive genomic profiling tests: FoundationOne CDx, the OncoGuide NCC Oncopanel System, or the GenMine TOP Cancer Genome Profiling System. Based on the reported TMB values, patients were classified as TMB‐high (≥ 10 mutations per megabase) or TMB‐low (< 10 mutations per megabase). The objective response rate (ORR) among 946 TMB‐high patients exceeded 30% and was significantly higher than that observed in 953 TMB‐low patients (16.8%, p < 0.001). Notably, patients with borderline TMB values (10 to less than 13 mutations per megabase) exhibited relatively modest responses (20.8%). The ORR improved when hotspot mutations were excluded from the TMB calculation, suggesting that this adjustment enhances the predictive accuracy of TMB. These findings support the clinical utility of TMB as a biomarker for predicting ICI response in routine oncology practice. In particular, excluding hotspot mutations from TMB calculations may improve response prediction in patients whose TMB values are near the threshold.
7 November 2023 in medRxiv
Summary: Background: Endogenous retroelements (EREs), including human endogenous retroviruses (HERVs) and long interspersed nuclear elements (LINEs), comprise almost half of the human genome. HIV-1 infects a target cell already possessing ancient retroviral genetic material, and exogenous HIV-1 infection modulates the expression of cell associated EREs. Following initial HIV-1 infection, there is a rapid destruction of CD4+ cells in the gut associated lymphoid tissue (GALT). Our previous studies of the interferome in the gut suggest potential mechanisms regarding how IFNb may drive HIV-1 gut pathogenesis. As ERE activity is suggested to partake in type 1 immune responses and is incredibly sensitive to viral infections, we sought to elucidate underlying interactions between ERE expression and GALT dynamics in PLWH. Methods: ERE expression profiles from bulk RNA sequencing of colon biopsies and PBMC were compared between a cohort of PLWH prior to or within 7 days of initiating antiretroviral therapy (ART) (n=19) and uninfected controls (n=13). Individual EREs were then compared with the profiling of uninfected gut CD4+ T cells activated with type 1 interferons (IFN-Is) (n=3) to elucidate potential mechanisms for their induction in PLWH. Findings: 59 EREs were differentially expressed in the colon of PLWH when compared to uninfected controls (Wald’s Test with Benjamin-Hochberg correction: padj < 0.05 and FC ≤ −1 or ≥ 1). Of these 59, 12 EREs were downregulated in PLWH and 47 were upregulated. Colonic expression of the ERE loci LTR19_12p13.31 and L1FLnI_1q23.1s showed significant correlations with CD8+ T Cells and dendritic cell subset frequencies in the GI tract (Spearman’s Correlation: p value < 0.05). Furthermore L1FLnI_1q23.1s showed a significant upregulation in the blood of PLWH when compared to uninfected controls (T test: p <0.05) suggesting a common mechanism of differential ERE expression in PBMC and GALT. Interpretation: ERE activity has been largely understudied in genomic characterizations of human pathologies. We show that the activity of certain EREs in the GI tract of PLWH is deregulated, supporting our hypotheses that their underlying activity could function as (bio)markers and potential mediators of pathogenesis in HIV-1 reservoirs. Funding: NCI CA260691 (DFN) and NIAID UM1AI164559 (DFN).